Biofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care.
Biofrontera Inc., located in Woburn, MA, is the wholly owned US-subsidiary of Biofrontera AG, Germany, a pharmaceutical company specializing in the development and commercialization of dermatological drugs. Biofrontera, Inc. was founded in March 2015 to commercialize the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, in the United States. In 2019, Biofrontera Inc. expanded its US-product portfolio with the FDA-approved drug Xepi™ (ozenoxacin) cream, 1%. With both FDA-approved products offering multi-billion-dollar market opportunities, Biofrontera Inc. is ideally positioned for sustainable growth. Our promising pipeline has the ability to continue to cover patient needs in dermatology.
Our vision at Biofrontera Inc. is to be a trusted partner who brings unparalleled therapies and service to patients and healthcare providers in the dermatology community.
Biofrontera Inc. will become a leading US specialty dermatology company by focusing on developing innovative therapy options that enable dermatology healthcare professionals to help improve the lives of their patients.